A personalized approach to acute myeloid leukemia therapy: current options

Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic land...

Descripción completa

Detalles Bibliográficos
Autores principales: Illangeswaran, Raveen Stephen Stallon, Das, Saswati, Paul, Daniel Zechariah, Mathews, Vikram, Balasubramanian, Poonkuzhali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684879/
https://www.ncbi.nlm.nih.gov/pubmed/31447578
http://dx.doi.org/10.2147/PGPM.S168267
_version_ 1783442318972420096
author Illangeswaran, Raveen Stephen Stallon
Das, Saswati
Paul, Daniel Zechariah
Mathews, Vikram
Balasubramanian, Poonkuzhali
author_facet Illangeswaran, Raveen Stephen Stallon
Das, Saswati
Paul, Daniel Zechariah
Mathews, Vikram
Balasubramanian, Poonkuzhali
author_sort Illangeswaran, Raveen Stephen Stallon
collection PubMed
description Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab–ozogamicin, and CPX351 by the US Food and Drug Administration has widened the treatment options for clinicians treating AML. This review focuses on some of these novel therapies and other promising agents under development, along with key clinical trial findings in AML.
format Online
Article
Text
id pubmed-6684879
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66848792019-08-23 A personalized approach to acute myeloid leukemia therapy: current options Illangeswaran, Raveen Stephen Stallon Das, Saswati Paul, Daniel Zechariah Mathews, Vikram Balasubramanian, Poonkuzhali Pharmgenomics Pers Med Review Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab–ozogamicin, and CPX351 by the US Food and Drug Administration has widened the treatment options for clinicians treating AML. This review focuses on some of these novel therapies and other promising agents under development, along with key clinical trial findings in AML. Dove 2019-08-02 /pmc/articles/PMC6684879/ /pubmed/31447578 http://dx.doi.org/10.2147/PGPM.S168267 Text en © 2019 Illangeswaran et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Illangeswaran, Raveen Stephen Stallon
Das, Saswati
Paul, Daniel Zechariah
Mathews, Vikram
Balasubramanian, Poonkuzhali
A personalized approach to acute myeloid leukemia therapy: current options
title A personalized approach to acute myeloid leukemia therapy: current options
title_full A personalized approach to acute myeloid leukemia therapy: current options
title_fullStr A personalized approach to acute myeloid leukemia therapy: current options
title_full_unstemmed A personalized approach to acute myeloid leukemia therapy: current options
title_short A personalized approach to acute myeloid leukemia therapy: current options
title_sort personalized approach to acute myeloid leukemia therapy: current options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684879/
https://www.ncbi.nlm.nih.gov/pubmed/31447578
http://dx.doi.org/10.2147/PGPM.S168267
work_keys_str_mv AT illangeswaranraveenstephenstallon apersonalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT dassaswati apersonalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT pauldanielzechariah apersonalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT mathewsvikram apersonalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT balasubramanianpoonkuzhali apersonalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT illangeswaranraveenstephenstallon personalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT dassaswati personalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT pauldanielzechariah personalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT mathewsvikram personalizedapproachtoacutemyeloidleukemiatherapycurrentoptions
AT balasubramanianpoonkuzhali personalizedapproachtoacutemyeloidleukemiatherapycurrentoptions

Ejemplares similares